Screener
Rigel Pharmaceuticals RIGL Single reportable segment — Net Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest expense | (1,433) | (1,853) |
| Income before income taxes | 11,657 | 11,511 |
| Provision for income taxes | 3,003 | 65 |
| Net income | $8,654 | $11,446 |
| Net income per share | ||
| Basic | $0.47 | $0.64 |
| Diluted | $0.44 | $0.63 |
| Weighted average shares used in computing net income per share |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's single reportable segment — net income?
- Rigel Pharmaceuticals (RIGL) reported single reportable segment — net income of $8.65M in Q1 2026.
- What does single reportable segment — net income mean?
- Calculated as the total revenue minus all operating expenses, taxes, and interest costs for the reportable segment. This is the primary measure of the segment's overall financial health and profitability.
Ask your AI about Rigel Pharmaceuticals's single reportable segment — net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude